Without exception, national and managed healthcare system guidelines ask companies making a submission for formulary listing and reimbursement to supplement their drug comparator analysis with an assessment of the anticipated impact of the drug on the formulary or health system budget. The Australian guidelines, for example, ask (in Section 4) for an assessment of the estimated use of a drug and the financial implications of this for the Pharmaceutical Benefits Scheme (PBS) and for government health budgets.1